{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:40:23Z","timestamp":1746189623689,"version":"3.40.4"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.oftale.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:28:28Z","timestamp":1741364908000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center"],"prefix":"10.1016","volume":"100","author":[{"given":"P.D.","family":"Lara-Barrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Tovilla-Canales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Olvera-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.G.","family":"Castillo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Nava-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2025.03.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2022.103302","article-title":"Altered brain connectivity in hyperkinetic movement disorders: a review of resting-state fMRI","volume":"37","author":"Marapin","year":"2023","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.oftale.2025.03.009_bib0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0036-1571952","article-title":"Botulinum toxin treatment of blepharospasm, orofacial\/oromandibular dystonia, and hemifacial spasm","volume":"36","author":"Karp","year":"2016","journal-title":"Semin Neurol."},{"key":"10.1016\/j.oftale.2025.03.009_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5334\/tohm.273","article-title":"Systematic literature review of abobotulinumtoxina in clinical trials for blepharospasm and hemifacial spasm","volume":"5","author":"Dashtipour","year":"2015","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"key":"10.1016\/j.oftale.2025.03.009_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2017.04.036","article-title":"Role of the \u201cother Babinski sign\u201d in hyperkinetic facial disorders","volume":"378","author":"Varanda","year":"2017","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.oftale.2025.03.009_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuchi.2017.12.003","article-title":"Diagnosis of primary hemifacial spasm","volume":"64","author":"Lefaucheur","year":"2018","journal-title":"Neurochirurgie."},{"key":"10.1016\/j.oftale.2025.03.009_bib0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov Disord."},{"key":"10.1016\/j.oftale.2025.03.009_bib0035","article-title":"Botulinum toxin type A therapy for blepharospasm","volume":"11","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.oftale.2025.03.009_bib0040","first-page":"131","article-title":"Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin","volume":"28","author":"Polo","year":"2013","journal-title":"Neurologia."},{"key":"10.1016\/j.oftale.2025.03.009_bib0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1590\/S0004-282X2012000900003","article-title":"Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience","volume":"70","author":"Aquino","year":"2012","journal-title":"Arq Neuropsiquiatr."},{"issue":"2A","key":"10.1016\/j.oftale.2025.03.009_bib0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1590\/S0004-282X2005000200006","article-title":"Botulinum toxin a in the treatment of blepharospasm: a 10-year experience","volume":"63","author":"Silveira-Moriyama","year":"2005","journal-title":"Arq Neuropsiquiatr."},{"key":"10.1016\/j.oftale.2025.03.009_bib0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","article-title":"Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs","volume":"15","author":"Bentivoglio","year":"2009","journal-title":"Neurotox Res."},{"key":"10.1016\/j.oftale.2025.03.009_bib0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2013.02.001","article-title":"Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome","volume":"156","author":"Czyz","year":"2013","journal-title":"Am J Ophthalmol."}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579425000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579425000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:25:55Z","timestamp":1746109555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579425000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2173579425000350"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2025.03.009","relation":{},"ISSN":["2173-5794"],"issn-type":[{"type":"print","value":"2173-5794"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2024.12.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}